ID   MBOA5_HUMAN             Reviewed;         487 AA.
AC   Q6P1A2; B2RDH0; B7Z3N3; Q7KZS1; Q92980; Q9BW40;
DT   02-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   12-APR-2017, entry version 119.
DE   RecName: Full=Lysophospholipid acyltransferase 5;
DE            Short=LPLAT 5;
DE            EC=2.3.1.-;
DE   AltName: Full=1-acylglycerophosphocholine O-acyltransferase;
DE            EC=2.3.1.23;
DE   AltName: Full=1-acylglycerophosphoserine O-acyltransferase;
DE            EC=2.3.1.n6;
DE   AltName: Full=Lysophosphatidylcholine acyltransferase;
DE            Short=LPCAT;
DE            Short=Lyso-PC acyltransferase;
DE   AltName: Full=Lysophosphatidylcholine acyltransferase 3;
DE            Short=Lyso-PC acyltransferase 3;
DE   AltName: Full=Lysophosphatidylserine acyltransferase;
DE            Short=LPSAT;
DE            Short=Lyso-PS acyltransferase;
DE   AltName: Full=Membrane-bound O-acyltransferase domain-containing protein 5;
DE            Short=O-acyltransferase domain-containing protein 5;
GN   Name=LPCAT3; Synonyms=MBOAT5, OACT5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4] {ECO:0000312|EMBL:AAH65194.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon {ECO:0000312|EMBL:AAH00664.2}, and
RC   Pancreas {ECO:0000312|EMBL:AAH65194.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAC51640.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 50-487 (ISOFORM 1).
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAP35646.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 107-487 (ISOFORM 1/2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   IDENTIFICATION, FUNCTION, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND TISSUE SPECIFICITY.
RX   PubMed=18195019; DOI=10.1074/jbc.M710422200;
RA   Zhao Y., Chen Y.Q., Bonacci T.M., Bredt D.S., Li S., Bensch W.R.,
RA   Moller D.E., Kowala M., Konrad R.J., Cao G.;
RT   "Identification and characterization of a major liver
RT   lysophosphatidylcholine acyltransferase.";
RL   J. Biol. Chem. 283:8258-8265(2008).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, AND SUBSTRATE SPECIFICITY.
RX   PubMed=18772128; DOI=10.1074/jbc.M806194200;
RA   Gijon M.A., Riekhof W.R., Zarini S., Murphy R.C., Voelker D.R.;
RT   "Lysophospholipid acyltransferases and arachidonate recycling in human
RT   neutrophils.";
RL   J. Biol. Chem. 283:30235-30245(2008).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Acyltransferase which mediates the conversion of
CC       lysophosphatidylcholine (1-acyl-sn-glycero-3-phosphocholine or
CC       LPC) into phosphatidylcholine (1,2-diacyl-sn-glycero-3-
CC       phosphocholine or PC) (LPCAT activity). Catalyzes also the
CC       conversion of lysophosphatidylserine (1-acyl-2-hydroxy-sn-glycero-
CC       3-phospho-L-serine or LPS) into phosphatidylserine (1,2-diacyl-sn-
CC       glycero-3-phospho-L-serine or PS) (LPSAT activity). Has also weak
CC       lysophosphatidylethanolamine acyltransferase activity (LPEAT
CC       activity). Favors polyunsaturated fatty acyl-CoAs as acyl donors
CC       compared to saturated fatty acyl-CoAs. Seems to be the major
CC       enzyme contributing to LPCAT activity in the liver.
CC       Lysophospholipid acyltransferases (LPLATs) catalyze the
CC       reacylation step of the phospholipid remodeling pathway also known
CC       as the Lands cycle. {ECO:0000269|PubMed:18195019,
CC       ECO:0000269|PubMed:18772128}.
CC   -!- CATALYTIC ACTIVITY: Acyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CC       = CoA + 1,2-diacyl-sn-glycero-3-phosphocholine.
CC   -!- CATALYTIC ACTIVITY: Acyl-CoA + 1-acyl-sn-glycero-3-
CC       phosphatidylserine = CoA + 1,2-diacyl-sn-glycero-3-
CC       phosphatidylserine.
CC   -!- ENZYME REGULATION: Activity is inhibited by thimerosal.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=41.29 uM for palmitoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=36.65 uM for stearoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=72.68 uM for oleoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=201.4 uM for linoleoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=71.56 uM for arachidonoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=72.19 uM for 1-palmitoyl-lysophosphatidylcholine
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=1782 nmol/min/mg enzyme with palmitoyl-CoA and 1-palmitoyl-
CC         lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=996 nmol/min/mg enzyme with stearoyl-CoA and 1-palmitoyl-
CC         lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=4698 nmol/min/mg enzyme with oleoyl-CoA and 1-palmitoyl-
CC         lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=18148 nmol/min/mg enzyme with linoleoyl-CoA and 1-
CC         palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=6247 nmol/min/mg enzyme with arachidonoyl-CoA and 1-
CC         palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC   -!- PATHWAY: Lipid metabolism; phospholipid metabolism.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:18195019}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:18195019}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6P1A2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6P1A2-2; Sequence=VSP_053680;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver, pancreas and
CC       adipose tissue. Very low expression in skeletal muscle and heart.
CC       Detected in neutrophils. {ECO:0000269|PubMed:18195019,
CC       ECO:0000269|PubMed:18772128}.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum
CC       localization.
CC   -!- SIMILARITY: Belongs to the membrane-bound acyltransferase family.
CC       {ECO:0000255}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB51326.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAC51640.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAG37917.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BX648009; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK296145; BAH12269.1; -; mRNA.
DR   EMBL; AK315538; BAG37917.1; ALT_INIT; mRNA.
DR   EMBL; AC006512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000664; AAH00664.2; -; mRNA.
DR   EMBL; BC065194; AAH65194.1; -; mRNA.
DR   EMBL; U47924; AAB51326.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U72515; AAC51640.1; ALT_INIT; mRNA.
DR   EMBL; BT007000; AAP35646.1; -; mRNA.
DR   CCDS; CCDS8572.1; -. [Q6P1A2-1]
DR   RefSeq; NP_005759.4; NM_005768.5. [Q6P1A2-1]
DR   UniGene; Hs.655248; -.
DR   ProteinModelPortal; Q6P1A2; -.
DR   BioGrid; 115464; 20.
DR   IntAct; Q6P1A2; 4.
DR   MINT; MINT-3049790; -.
DR   STRING; 9606.ENSP00000261407; -.
DR   SwissLipids; SLP:000000127; -.
DR   iPTMnet; Q6P1A2; -.
DR   PhosphoSitePlus; Q6P1A2; -.
DR   BioMuta; LPCAT3; -.
DR   DMDM; 74737127; -.
DR   EPD; Q6P1A2; -.
DR   MaxQB; Q6P1A2; -.
DR   PaxDb; Q6P1A2; -.
DR   PeptideAtlas; Q6P1A2; -.
DR   PRIDE; Q6P1A2; -.
DR   DNASU; 10162; -.
DR   Ensembl; ENST00000261407; ENSP00000261407; ENSG00000111684. [Q6P1A2-1]
DR   GeneID; 10162; -.
DR   KEGG; hsa:10162; -.
DR   UCSC; uc001qsi.4; human. [Q6P1A2-1]
DR   CTD; 10162; -.
DR   DisGeNET; 10162; -.
DR   GeneCards; LPCAT3; -.
DR   H-InvDB; HIX0129675; -.
DR   HGNC; HGNC:30244; LPCAT3.
DR   MIM; 611950; gene.
DR   neXtProt; NX_Q6P1A2; -.
DR   OpenTargets; ENSG00000111684; -.
DR   PharmGKB; PA162394266; -.
DR   eggNOG; KOG2705; Eukaryota.
DR   eggNOG; COG5202; LUCA.
DR   GeneTree; ENSGT00550000074565; -.
DR   HOGENOM; HOG000019529; -.
DR   HOVERGEN; HBG054659; -.
DR   InParanoid; Q6P1A2; -.
DR   KO; K13515; -.
DR   OMA; YLIVCQV; -.
DR   OrthoDB; EOG091G062X; -.
DR   PhylomeDB; Q6P1A2; -.
DR   TreeFam; TF106143; -.
DR   BRENDA; 2.3.1.23; 2681.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   SABIO-RK; Q6P1A2; -.
DR   UniPathway; UPA00085; -.
DR   ChiTaRS; LPCAT3; human.
DR   GeneWiki; MBOAT5; -.
DR   GenomeRNAi; 10162; -.
DR   PRO; PR:Q6P1A2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000111684; -.
DR   CleanEx; HS_LPCAT3; -.
DR   ExpressionAtlas; Q6P1A2; baseline and differential.
DR   Genevisible; Q6P1A2; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0003841; F:1-acylglycerol-3-phosphate O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0047184; F:1-acylglycerophosphocholine O-acyltransferase activity; IMP:MGI.
DR   GO; GO:0047144; F:2-acylglycerol-3-phosphate O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036152; P:phosphatidylethanolamine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036150; P:phosphatidylserine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0008654; P:phospholipid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0097006; P:regulation of plasma lipoprotein particle levels; IEA:Ensembl.
DR   InterPro; IPR004299; MBOAT_fam.
DR   Pfam; PF03062; MBOAT; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Acyltransferase; Alternative splicing; Complete proteome;
KW   Endoplasmic reticulum; Lipid biosynthesis; Lipid metabolism; Membrane;
KW   Phospholipid biosynthesis; Phospholipid metabolism; Polymorphism;
KW   Reference proteome; Transferase; Transmembrane; Transmembrane helix.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712}.
FT   CHAIN         2    487       Lysophospholipid acyltransferase 5.
FT                                /FTId=PRO_0000233382.
FT   TRANSMEM     44     64       Helical. {ECO:0000255}.
FT   TRANSMEM     84    104       Helical. {ECO:0000255}.
FT   TRANSMEM    111    131       Helical. {ECO:0000255}.
FT   TRANSMEM    180    200       Helical. {ECO:0000255}.
FT   TRANSMEM    227    247       Helical. {ECO:0000255}.
FT   TRANSMEM    285    305       Helical. {ECO:0000255}.
FT   TRANSMEM    364    384       Helical. {ECO:0000255}.
FT   TRANSMEM    422    442       Helical. {ECO:0000255}.
FT   TRANSMEM    453    473       Helical. {ECO:0000255}.
FT   MOTIF       484    487       Di-lysine motif.
FT   ACT_SITE    338    338       {ECO:0000250}.
FT   ACT_SITE    374    374       {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:25944712}.
FT   VAR_SEQ      21    100       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_053680.
FT   VARIANT      63     63       F -> L (in dbSNP:rs34196984).
FT                                /FTId=VAR_050027.
FT   VARIANT     217    217       I -> T (in dbSNP:rs1984564).
FT                                /FTId=VAR_050028.
FT   CONFLICT    387    387       E -> K (in Ref. 4; AAH00664 and 6;
FT                                AAP35646). {ECO:0000305}.
SQ   SEQUENCE   487 AA;  56035 MW;  429258B54585B4A7 CRC64;
     MASSAEGDEG TVVALAGVLQ SGFQELSLNK LATSLGASEQ ALRLIISIFL GYPFALFYRH
     YLFYKETYLI HLFHTFTGLS IAYFNFGNQL YHSLLCIVLQ FLILRLMGRT ITAVLTTFCF
     QMAYLLAGYY YTATGNYDIK WTMPHCVLTL KLIGLAVDYF DGGKDQNSLS SEQQKYAIRG
     VPSLLEVAGF SYFYGAFLVG PQFSMNHYMK LVQGELIDIP GKIPNSIIPA LKRLSLGLFY
     LVGYTLLSPH ITEDYLLTED YDNHPFWFRC MYMLIWGKFV LYKYVTCWLV TEGVCILTGL
     GFNGFEEKGK AKWDACANMK VWLFETNPRF TGTIASFNIN TNAWVARYIF KRLKFLGNKE
     LSQGLSLLFL ALWHGLHSGY LVCFQMEFLI VIVERQAARL IQESPTLSKL AAITVLQPFY
     YLVQQTIHWL FMGYSMTAFC LFTWDKWLKV YKSIYFLGHI FFLSLLFILP YIHKAMVPRK
     EKLKKME
//
